Two patients with Canavan disease and structural modeling of a novel mutation

Osama K. Zaki, Navaneethakrishnan Krishnamoorthy, Heba S. El Abd, Soumaya A. Harche, Reem A. Mattar, Rana S. Al Disi, Mariam Y. Nofal, Rajaa El Bekay, Khalid A. Ahmed, C. George Priya Doss, Hatem Zayed

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalMetabolic Brain Disease
DOIs
Publication statusAccepted/In press - 17 Aug 2016
Externally publishedYes

Fingerprint

Canavan Disease
Mutation
Missense Mutation
Inborn Genetic Diseases
Molecular modeling
Ports and harbors
Ethnic Groups
Aspartic Acid
Hydrolysis
Acetates
Genes
Enzymes
Population
Proteins

Keywords

  • Aspartoacylase
  • Canavan disease
  • In silico mutagenesis
  • Molecular modeling
  • MRI
  • MRS
  • N-acetyl-aspartate

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Zaki, O. K., Krishnamoorthy, N., El Abd, H. S., Harche, S. A., Mattar, R. A., Al Disi, R. S., ... Zayed, H. (Accepted/In press). Two patients with Canavan disease and structural modeling of a novel mutation. Metabolic Brain Disease, 1-7. https://doi.org/10.1007/s11011-016-9896-9

Two patients with Canavan disease and structural modeling of a novel mutation. / Zaki, Osama K.; Krishnamoorthy, Navaneethakrishnan; El Abd, Heba S.; Harche, Soumaya A.; Mattar, Reem A.; Al Disi, Rana S.; Nofal, Mariam Y.; El Bekay, Rajaa; Ahmed, Khalid A.; George Priya Doss, C.; Zayed, Hatem.

In: Metabolic Brain Disease, 17.08.2016, p. 1-7.

Research output: Contribution to journalArticle

Zaki, OK, Krishnamoorthy, N, El Abd, HS, Harche, SA, Mattar, RA, Al Disi, RS, Nofal, MY, El Bekay, R, Ahmed, KA, George Priya Doss, C & Zayed, H 2016, 'Two patients with Canavan disease and structural modeling of a novel mutation', Metabolic Brain Disease, pp. 1-7. https://doi.org/10.1007/s11011-016-9896-9
Zaki, Osama K. ; Krishnamoorthy, Navaneethakrishnan ; El Abd, Heba S. ; Harche, Soumaya A. ; Mattar, Reem A. ; Al Disi, Rana S. ; Nofal, Mariam Y. ; El Bekay, Rajaa ; Ahmed, Khalid A. ; George Priya Doss, C. ; Zayed, Hatem. / Two patients with Canavan disease and structural modeling of a novel mutation. In: Metabolic Brain Disease. 2016 ; pp. 1-7.
@article{286f8962a57e44c7bddec72ad60aba63,
title = "Two patients with Canavan disease and structural modeling of a novel mutation",
abstract = "Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.",
keywords = "Aspartoacylase, Canavan disease, In silico mutagenesis, Molecular modeling, MRI, MRS, N-acetyl-aspartate",
author = "Zaki, {Osama K.} and Navaneethakrishnan Krishnamoorthy and {El Abd}, {Heba S.} and Harche, {Soumaya A.} and Mattar, {Reem A.} and {Al Disi}, {Rana S.} and Nofal, {Mariam Y.} and {El Bekay}, Rajaa and Ahmed, {Khalid A.} and {George Priya Doss}, C. and Hatem Zayed",
year = "2016",
month = "8",
day = "17",
doi = "10.1007/s11011-016-9896-9",
language = "English",
pages = "1--7",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",

}

TY - JOUR

T1 - Two patients with Canavan disease and structural modeling of a novel mutation

AU - Zaki, Osama K.

AU - Krishnamoorthy, Navaneethakrishnan

AU - El Abd, Heba S.

AU - Harche, Soumaya A.

AU - Mattar, Reem A.

AU - Al Disi, Rana S.

AU - Nofal, Mariam Y.

AU - El Bekay, Rajaa

AU - Ahmed, Khalid A.

AU - George Priya Doss, C.

AU - Zayed, Hatem

PY - 2016/8/17

Y1 - 2016/8/17

N2 - Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.

AB - Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.

KW - Aspartoacylase

KW - Canavan disease

KW - In silico mutagenesis

KW - Molecular modeling

KW - MRI

KW - MRS

KW - N-acetyl-aspartate

UR - http://www.scopus.com/inward/record.url?scp=84982174869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982174869&partnerID=8YFLogxK

U2 - 10.1007/s11011-016-9896-9

DO - 10.1007/s11011-016-9896-9

M3 - Article

C2 - 27531131

AN - SCOPUS:84982174869

SP - 1

EP - 7

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

ER -